Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
195.47B
Market cap195.47B
Price-Earnings ratio
11.04
Price-Earnings ratio11.04
Dividend yield
2.61%
Dividend yield2.61%
Average volume
10.74M
Average volume10.74M
High today
$49.15
High today$49.15
Low today
$43.68
Low today$43.68
Open price
$47.57
Open price$47.57
Volume
47.48M
Volume47.48M
52 Week high
$64.16
52 Week high$64.16
52 Week low
$35.12
52 Week low$35.12

NVO News

TipRanks 3h
Novo Nordisk Lifts 2026 Guidance as Wegovy Pill Drives Q2 Obesity Growth

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

MarketWatch 5h
The Wegovy pill’s ‘surprise miss’ is one reason Novo Nordisk’s stock is down

Novo Nordisk’s Wegovy pill saw lower-than-expected sales that surprised investors, although it’s been held up as the most successful drug launch of all time. I...

The Wegovy pill’s ‘surprise miss’ is one reason Novo Nordisk’s stock is down
Benzinga 6h
Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks

Novo Nordisk A/S (NYSE:NVO) stock is trading lower on Tuesday despite the company raising its fiscal 2026 guidance. The weight loss drug maker reported second...

Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks

Analyst ratings

57%

of 37 ratings
Buy
37.8%
Hold
56.8%
Sell
5.4%

More NVO News

Investor's Business Daily 7h
Novo Nordisk Dives 6% After Unexpectedly Releasing Earnings A Day Early

Technology Novo Nordisk Dives 6% After Unexpectedly Releasing Earnings A Day Early Licensing Novo Nordisk (NVO) stock plummeted Tuesday after the obesity kingpi...

Novo Nordisk Dives 6% After Unexpectedly Releasing Earnings A Day Early
CNBC 7h
Novo Nordisk shares slide after guidance disappoints investors

Novo Nordisk CEO Maziar Mike Doustdar waits for the start of the pharmaceutical company’s annual general meeting in Copenhagen, Denmark, March 26, 2026. U.S.-t...

Novo Nordisk shares slide after guidance disappoints investors
Seeking Alpha 7h
Novo Nordisk slips despite lifting guidance on GLP-1 strength

Novo Nordisk (NVO) raised its full-year outlook for the second time this year, citing increased expectations for GLP-1 product sales. The Danish drugmaker now...

Novo Nordisk slips despite lifting guidance on GLP-1 strength
The Wall Street Journal 8h
Wegovy Maker Novo Nordisk Lifts Guidance After Second-Quarter Boost

Novo Nordisk said it expected sales and operating profit on an adjusted basis to decline up to 6% at constant exchange rates this year. Tom Little / Reuters No...

Wegovy Maker Novo Nordisk Lifts Guidance After Second-Quarter Boost
TipRanks 8h
Novo Nordisk Probes Thyroid Cancer Risk in Real‑World GLP‑1 Users

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident i...

TipRanks 2d
Novo Nordisk: Neutral Rating Maintained as Obesity Franchise Faces GLP‑1 Competition and Shares Trade Near DKK 350 Target

Bank of America Securities analyst Sachin Jain has maintained their neutral stance on 0QIU stock, giving a Hold rating on July 31. Unlock powerful investing to...

Simply Wall St 3d
Novo Nordisk Ziltivekimab Trial Fails In Late Stage Cardiovascular Study

Novo Nordisk (NYSE:NVO) reported that its late stage ZEUS trial of ziltivekimab in patients with atherosclerotic cardiovascular disease and chronic kidney disea...

Novo Nordisk Ziltivekimab Trial Fails In Late Stage Cardiovascular Study

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.